A Clinicopathological Study to Assess the Role of Intralesional Sclerotherapy Following Propranolol Treatment in Infantile Hemangioma

• Published in: Journal of cutaneous and aesthetic surgery 2021-10, Vol.14 (4), p.409-415
• Main Authors: Kumar, Rakesh, Tiwari, Preeti, Pandey, Vaibhav, Kar, Amrita Ghosh, Tiwary, Narendra, Sharma, Shiv Prasad
• Format: Article
• Language: English
• Subjects: Care and treatment; Corticosteroids; Hemangioma; Medical research; Medicine, Experimental; Original; Propranolol hydrochloride; Triamcinolone; Vincristine
• ISSN: 0974-2077; 0974-5157
• DOI: 10.4103/JCAS.JCAS_103_20

As propranolol has emerged as first-line therapy for problematic infantile hemangioma, the number of non-responders and partial responders to propranolol therapy is also increasing. The study was conducted to evaluate the response of intralesional bleomycin, triamcinolone, and a combination of both as second line of treatment for the residual hemangioma following propranolol therapy. A prospective comparative study was conducted in patients who were either non-responders or partial responders to previous propranolol treatment. The patients randomly received injection bleomycin, injection triamcinolone, and combination of both bleomycin and triamcinolone. The response to treatment was recorded clinically by using photographs. The pathological response was assessed by calculating pre-treatment and post-treatment microvessel density in biopsy of lesion from the non-cosmetic sites using immunohistochemistry. χ test was used to test the association between the variables. The utility of microvessel diameter (MVD) in terms of clinical response to the therapy was predicted by using receiver operating characteristic (ROC) curve. Out of the 134 patients, 42 received bleomycin and 44 received triamcinolone and were treated with a combination of both. The overall clinical response was better in the combination group compared with the bleomycin group ( = 0.018) and triamcinolone group ( = 0.0005), respectively, after 6 months of follow-up. There was no difference in clinical response between the triamcinolone and bleomycin groups. Change in MVD correlated with the clinical response. The combination of bleomycin and triamcinolone is effective and safe for the treatment of residual hemangioma.